↧
Image may be NSFW.
Clik here to view.
Clik here to view.
Synta readying two key lung cancer trials
CEO Dr. Safi Bahcall Synta Pharmaceuticals (NASDAQ:SNTA) is gearing up to begin two key clinical trials in non-small cell lung cancer (NSCLC) with its two novel compounds – ganetespib and elesclomol –...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Synta’s ganetespib shows activity in lung cancer
Synta Pharmaceuticals (NASDAQ:SNTA) has presented results at the annual meeting of ASCO from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer that showed...
View Article